Cited by 162Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesCancer-related Molecular Pathways

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

Bally, Cecile, Adès, Lionel, Renneville, Aline, Sebert, Marie, Eclache, Virginie, Preudhomme, Claude, Mozziconacci, Marie-Joelle, de The, Hugues, Lehmann-Che, Jacqueline, Fenaux, Pierre·2014·Leukemia Research

DOI 10.1016/j.leukres.2014.03.012

Open this paper in CoChat — free account

Abstract

TP53 mutations are found in 5-10% of MDS and AML, where they are generally associated with complex karyotype and an overall poor prognosis. However, the impact of TP53 mutations in MDS treated with azacitidine (AZA) remains unclear. We analyzed TP53 mutations in 62 patients with high risk MDS or AML treated with AZA. A TP53 mutation was found in 23 patients (37.1%), associated with complex karyotype in 18 (78.3%) of them. TP53 mutations had no significant impact on response or complete response to AZA (p=0.60 and p=0.26, respectively). By univariate analysis, OS was negatively influenced by the presence of TP53 mutation (median OS 12.4 months versus 23.7 months, p<10(-4)), abnormal cytogenetics (median OS 14.4 months vs 33 months, p=0.02) complex cytogenetics (median OS 12.7 months versus 23.7 months, p=0.0005), and a diagnosis of AML (median 14.5 months vs 21.2 months for MDS or CMML, p=0.02). By multivariate analysis, only TP53 mutational status (HR 2.89 (95% confidence interval 1.38-6.04; p=0.005) retained statistical significance for OS. Results were similar when the analysis was restricted to MDS and CMML patients, excluding AML (HR=2.46 (95% confidence interval: 1.1-6.4); p=0.04)). Thus, TP53 mutations strongly correlated with poorer survival in higher risk MDS and AML treated with AZA.

Integrity signals

Registry

Crossref · 10.1016/j.leukres.2014.03.012

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Self-citation
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319
p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies
Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 592
Self-citation
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Fenaux, P., Giagounidis, A. A. N., Selleslag, D., Beyne‐Rauzy, O., Mufti, G. J., Mittelman, M., Muus, P., Boekhorst, P. A. W. T., Sanz, G. F., del Cañizo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330126 · Cited by 497
Self-citation
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
Itzykson, R., Kosmider, O., Cluzeau, T., Mas, V. M., Dreyfus, F., Beyne‐Rauzy, O., Quesnel, B., Vey, N., Gelsi‐Boyer, V., Raynaud, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.71 · Cited by 480
Self-citation
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8576 · Cited by 463
A simple p53 functional assay for screening cell lines, blood, and tumors.
Flaman, J., Frébourg, T., Moreau, V., Charbonnier, F., Martin, C., Chappuis, P. O., Sappino, A. P., Limacher, I. M., Bron, L. P., & Benhattar, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3963 · Cited by 455
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
Itzykson, R., Thépot, S., Quesnel, B., Dreyfus, F., Beyne‐Rauzy, O., Turlure, P., Vey, N., Récher, C., Dartigeas, C., Legros, L., et al. (2010) · Blood · doi:10.1182/blood-2010-06-289280 · Cited by 381
Self-citation
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.
Shen, L.-L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., Ahmed, S. S., Zhu, W., Pierce, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4781 · Cited by 348

Flagged first, then by citations

Show all 30 references

1 of the 30 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–162 of 162

A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions
Bewersdorf, J. P., Mina, A. A., Stahl, M. F., & Zeidan, A. M. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01141-2 · Cited by 13
TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment
Zhang, L., Abro, B., Campbell, A., & Ding, Y. (2024) · Laboratory Medicine · doi:10.1093/labmed/lmae048 · Cited by 12
Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine—A Retrospective Analysis
Wiśniewski, K., Pruszczyk, K., Puła, B., Lech‐Marańda, E., & Góra‐Tybor, J. (2024) · Cancers · doi:10.3390/cancers16071333 · Cited by 9
Prognostic value of indoleamine 2,3 dioxygenase in patients with higher‐risk myelodysplastic syndromes treated with azacytidine
Müller‐Thomas, C., Heider, M., Piontek, G., Schlensog, M., Bassermann, F. C., Kirchner, T., Germing, U., Götze, K. S. S., & Rudelius, M. (2020) · British Journal of Haematology · doi:10.1111/bjh.16652 · Cited by 9
A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis
Yang, B. Y., Yu, R., Cai, L., Chi, X.-H., Liu, C., Yang, L., Wang, X., He, P. F., & Lu, X. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3102-y · Cited by 9
DNA Methyltransferase Inhibitors in Myeloid Cancer
Ørskov, A. D., & Grønbæk, K. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000282 · Cited by 8
TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Rahmé, R., Braun, T., Manfredi, J. J., & Fenaux, P. (2023) · Biomedicines · doi:10.3390/biomedicines11041152 · Cited by 9
Self-citation
New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide
Loiseau, C., Ali, A., & Itzykson, R. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.014 · Cited by 10
Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants
Nagourney, A. J., Gipoor, J. B., Evans, S. S., D’Amora, P., Duesberg, M., Bernard, P. J., Francisco, F. R., & Nagourney, R. A. (2023) · Genes · doi:10.3390/genes14030747 · Cited by 8
Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes
Kobbe, G., Schroeder, T. A., Rautenberg, C., Kaivers, J., Gattermann, N., Haas, R. R., & Germing, U. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1645004 · Cited by 7
The Evolving Landscape of Myelodysplastic Syndrome Prognostication
Shreve, J. T., & Nazha, A. (2020) · Clinical Hematology International · doi:10.2991/chi.d.200408.001 · Cited by 7
Life after hypomethylating agents in myelodysplastic syndrome
Santini, V. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000117 · Cited by 7
SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q
Talati, C., Sallman, D. A., & List, A. F. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.07.293 · Cited by 7
Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS)
Berg, T., Salter, B., Radford, M., Chen, H. T., & Leber, B. F. (2025) · Current Oncology · doi:10.3390/curroncol32060319 · Cited by 6
Overexpression of TP 53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia
van der Helm, L. H., Berger, G., Diepstra, A., Huls, G. A., & Vellenga, E. (2016) · British Journal of Haematology · doi:10.1111/bjh.14166 · Cited by 6
Molecular Testing in Patients with Suspected Myelodysplastic Syndromes
Moyo, T. K., & Savona, M. R. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0356-8 · Cited by 7
Mutations in DNA Methylation Pathway and Number of Driver Mutations Predict Response to Azacitidine in Myelodysplastic Syndromes
Cedena, M., Rapado, I., Santos‐Lozano, A., Ayala, R. M., Onecha, E., Abáigar, M., Such, E., Ramos, F., Cervera, J., Sanz, G. F., et al. (2017) · Leukemia Research · doi:10.1016/s0145-2126(17)30210-2 · Cited by 6
[Clinical implications and prognostic value of TP53 gene mutation and deletion in patients with myelodysplastic syndromes].
Hj, H., Zx, S., Li, B., Tj, Q., Zf, X., Hl, Z., Lw, F., Nb, H., Lj, P., Sq, Q., et al. (2019) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2019.03.010 · Cited by 6
IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
Leisch, M., Greil, R., & Pleyer, L. (2020) · British Journal of Haematology · doi:10.1111/bjh.16710 · Cited by 6
Do somatic mutations in de novo MDS predict for response to treatment?
Schroeder, M. A., & Dezern, A. E. (2015) · Hematology · doi:10.1182/asheducation-2015.1.317 · Cited by 6
Deep Molecular and In Silico Protein Analysis of p53 Alteration in Myelodysplastic Neoplasia and Acute Myeloid Leukemia
Madarász, K., Mótyán, J. A., Bedekovics, J., Miltényi, Z., Újfalusi, A., Méhes, G., & Mokánszki, A. (2022) · Cells · doi:10.3390/cells11213475 · Cited by 5
Novel high–risk acute myeloid leukemia subgroup with ERG amplification and Biallelic loss of TP53
Schandl, C. A., Mazzoni, S. A., Znoyko, I. Y., Nahhas, G. J., Chung, D., Ding, Y., Hess, B. T., & Wolff, D. J. (2023) · Cancer Genetics · doi:10.1016/j.cancergen.2023.01.004 · Cited by 5
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53
Mehta, A. K., & Konopleva, M. (2024) · Hematology · doi:10.1182/hematology.2024000557 · Cited by 5
Mutation-Driven Therapy in MDS
Swoboda, D. M., & Sallman, D. A. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00554-4 · Cited by 5
Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis
Cai, L., Zhao, X., Ai, L., & Wang, H. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00641-4 · Cited by 5
The beginning of a new therapeutic era in acute myeloid leukemia
Récher, C. (2021) · eJHaem · doi:10.1002/jha2.252 · Cited by 8
Impact of TP53 alteration on allogeneic hematopoietic cell transplantation outcomes for myelodysplastic syndromes
Zhou, C., Xu, L., Zhang, X., Chang, Y., Mo, X., Sun, Y., Huang, X., & Wang, Y. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02511-7 · Cited by 5
Myelodysplastic syndrome: Approach to diagnosis in the era of personalized medicine
Barone, P. D., & Patel, S. S. (2023) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2023.04.008 · Cited by 5
Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes
Bally, C., Renneville, A., Preudhomme, C., Legrand, M., Adès, L., de Thé, H., Fenaux, P., & Lehmann‐Che, J. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.07.001 · Cited by 5
Self-citation
Appropriate Clinical Strategies for Breast Cancer Coexisting with Acute Myeloid Leukemia in the Genomic-Molecular Era: A Case Report
Hu, G., Mallik, D. K., Yang, W., Hou, Y., Cheng, Z., Chen, P., Zhu, W., Wang, H., Shen, L., Zhang, H., et al. (2016) · Breast Care · doi:10.1159/000443494 · Cited by 4
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML
Tenti, E., Papayannidis, C., Marconi, G., Parisi, S., Simonetti, G., Paolini, S., Sartor, C., Ottaviani, E., Testoni, N., & Martinelli, G. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1258056 · Cited by 4
Decitabine-cedazuridine in patients with MDS and TP53 mutations
Urrutia, S., Sasaki, K., Bataller, Á., Kantarjian, H. M., Bravo, G. M., McCloskey, J. K., Griffiths, E. A., Yee, K. W. L., Zeidan, A. M., Savona, M. R., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017745 · Cited by 3
CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells
Zhou, J., Hu, T., Li, D., Li, S., Li, M., Shi, X. E., & Nakada, D. (2026) · Leukemia · doi:10.1038/s41375-025-02850-w · Cited by 5
Prognostic role of SCAMP family in acute myeloid leukemia
Qian, T., Cheng, Z., Quan, L., Zeng, T., Cui, L., Liu, Y., Si, C., Huang, W., Dai, Y., Chen, J., et al. (2020) · The Pharmacogenomics Journal · doi:10.1038/s41397-020-0149-2 · Cited by 3
Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes
Fang, K., Qi, J., Zhou, M., Zhang, Z., & Han, Y. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.09.013 · Cited by 3
Biomarkers and Methodologies for Monitoring Epigenetic Drug Effects in Cancer
Treppendahl, M. B., Kristensen, L. S., & Grønbæk, K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801899-6.00005-x · Cited by 3
Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?
Wermke, M., Gloaguen, S., & Platzbecker, U. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0276-z · Cited by 3
Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk‐Stratification and Management
Garcia‐Manero, G. (2026) · American Journal of Hematology · doi:10.1002/ajh.70405 · Cited by 4
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study
Sallman, D. A., Garcia‐Manero, G., Daver, N. G., Abboud, C. N., Stein, E. M., Larkin, K. T. M., Halpern, A. B., McCurdy, S. R., Malki, M. M. A., Murthy, G. S. G., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-00617 · Cited by 2
A line in shifting sand: Can we define and target TP53 mutated MDS?
Skuli, S. J., Matthews, A. H., Carroll, M. P., & Lai, C. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.10.009 · Cited by 2
Mutant p53 regulates a distinct gene set by a mode of genome occupancy that is shared with wild type
Rahmé, R., Resnick‐Silverman, L., Anguiano, V., Campbell, M. J., Fenaux, P., & Manfredi, J. J. (2025) · EMBO Reports · doi:10.1038/s44319-025-00375-y · Cited by 2
Self-citation
Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization
Sallman, D. A., & Padron, E. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.03.005 · Cited by 2
Targeting TP53 Mutations in Myelodysplastic Syndromes
Sallman, D. A. (2018) · The Hematologist · doi:10.1182/hem.v15.6.9077 · Cited by 2
Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine
Matsuoka, A., Tanibuchi, M., Yamazaki, I., & Taoka, T. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03317-9 · Cited by 2
Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes
Hasserjian, R. P., Buckstein, R. J., & Patnaik, M. M. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320113 · Cited by 2
Potential impact of the hypomethylating agent 5-azacitidine on chronic lymphocytic leukemia with del(17)(p)/del(p53) and subsequent therapy-related acute myeloid leukemia without these aberrations: a case report
Pfeilstöcker, M., Weichselbaum, R., Mühlberger, H., Menschel, E., & Keil, F. (2015) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-015-0201-0 · Cited by 1
Hematological Improvement is a Favorable Response to Azacitidine in Patients with Acute Myeloid Leukemias and Myelodysplastic Syndromes
Kostroma, I. I., Грицаев, С. В., Karyagina, E. V., Низамутдинова, А. С., Степановна, М. И., & Абдулкадыров, К. М. (2015) · Clinical oncohematology · doi:10.21320/2500-2139-2015-8-4-413-419 · Cited by 1
Not All TP53 Mutations Are Equal
Jivan, Y., & Lane, S. (2021) · The Hematologist · Cited by 1
Platelet Doubling After First Decitabine Cycle Predicts Response and Survival of Myelodysplastic Syndrome Patients
Lu, P., Deng, L., Meng, F., Wang, Y., Xiao, M., & Li, D. (2022) · Current Medical Science · doi:10.1007/s11596-022-2533-4 · Cited by 1
TP53 mutations and Azacitidine treatment: To be or not to be related?
Rigolin, G. M., & Cuneo, A. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.04.005 · Cited by 1
Involvement in pricing by municipal recreation agencies.
McCarville, R. E., & Smale, B. J. A. (1991) · Journal of applied recreation research · Cited by 1
Treatment with Hypomethylating Agents (HMA)
Germing, U., & Fenaux, P. (2018) · Hematologic malignancies · doi:10.1007/978-3-319-76879-3_10
Self-citation
Zusammenhänge zwischen TP53-Mutationsstatus, genetischer Instabilität und Prognose bei MDS und sekundärer AML mit komplex aberrantem Karyotyp
Schaab, R. (2020) · doi:10.53846/goediss-7883
Evolutionary Action Score of TP53 Mutations: Integrated Clinico-pathologic And Protein Structural Analysis in Myelodysplastic SyndromesPreprint
Kanagal‐Shamanna, R., Bravo, G. M., Katsonis, P., Sasaki, K., Class, C. A., Benton, C. B., Jabbour, E. J., Chien, K. S., Luthra, R., Bueso-Ramos, C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.08.194365
Treatment Algorithms for Higher-Risk Disease
Hambley, B. C., & Dezern, A. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-51878-3_9
Treatment of Relapsed and Refractory AML: Non-intensive Approach in Unfit Patients
Récher, C. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-72676-8_12
In the Pipeline: Emerging Therapy for MDS and MDS/MPN
Gill, H., Lee, E., & Mo, P. (2023) · Springer eBooks · doi:10.1007/978-981-99-3810-0_35
Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes
Matsumoto, T., Murakami, Y., Yoshida‐Sakai, N., Katsuchi, D., Kanazawa, K., Okamura, T., Imamura, Y., Ono, M., & Kuwano, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094583
TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches
Deshpande, S., Li, W. F., Song, J., Forsberg, M., Cerchione, C., Martinelli, G., & Konopleva, M. Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1735418
Leucémie myélomonocytaire chronique : rôle des molécules Dok-1 et Dok-2 en tant que suppresseurs de tumeur
Coppin, E. (2015) · theses.fr (ABES) · doi:10.70675/6957c36dz8f27z48f3z8280z053c2d8e66ec
Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms
Hershberger, K. K., Thibodeau, J., Su, Y., Ramakrishna, S. S. M., Singh, V., Sharma, A., Edwards, H. J., Ge, Y., & Yang, J. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118177
Sequential therapy with decitabine and an XPO-1 inhibitor followed by allogeneic hematopoietic stem cell transplantation in MDS with biallelic TP53 inactivation patients : a preliminary case series
Ren, Y., Lang, W., Xu, Y., Mei, C., Huang, X., Wang, S., Qian, J., & Tong, H. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00817-w

Authors: Bally, C., Adès, L., Renneville, A., Sebert, M., Eclache, V., Preudhomme, C., Mozziconacci, M.-J., de The, H., Lehmann-Che, J., & Fenaux, P.
Affiliations: Assistance Publique – Hôpitaux de Paris (FR)
Centre Hospitalier Universitaire de Lille (FR)
Corresponding author: Fenaux, Pierre
ORCID: Adès, Lionel
Renneville, Aline
Preudhomme, Claude
Fenaux, Pierre
Venue: Leukemia Research
Publisher: Elsevier BV
Published: 2014-07
Volume: 38
Issue: 7
Pages: 751-755
ISSN: 0145-2126 (ISSN-L)
DOI: 10.1016/j.leukres.2014.03.012
OpenAlex: W2062135903
Cited by: 162
References: 30
Citations by year: 2026: 7 · 2025: 6 · 2024: 9 · 2023: 16 · 2022: 7 · 2021: 16 · 2020: 18 · 2019: 9 · 2018: 15 · 2017: 19 · 2016: 13 · 2015: 21 · 2014: 5
FWCI: 13.71
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Leukemia Research (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords: TP53 mutation, myelodysplastic syndrome, acute myeloid leukemia, azacitidine, prognostic factors, overall survival, complex karyotype, cytogenetics, high-risk MDS, chronic myelomonocytic leukemia, treatment response
MeSH terms: Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, Azacitidine, Female, Humans, Male, Middle Aged, Mutation, Myelodysplastic Syndromes, Prognosis, Leukemia, Myeloid, Acute, Genes, p53

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks